RemeGen Co., Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jianmin Fang
- Full Time Employees
- 2,999
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 58 Middle Beijing Road Yantai People's Republic of China
- IPO Date
- Jan 21, 2021
- Website
- remegen.com
- Similar Companies
- Business
- RemeGen Co., Ltd. (688331.SH; 9995.HK; REGMF) develops, manufactures and commercializes innovative biologics for autoimmune diseases, oncology and ophthalmology; its core products include the BLyS/APRIL dual-target fusion protein telitacicept (RC18, Tai'ai) approved in China for systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis and primary Sjögren's syndrome; the HER2-targeting antibody-drug conjugate disitamab vedotin (RC48, Aidixi) approved for HER2-positive urothelial and gastric cancers; the anti-VEGF/angiopoietin-2 bispecific antibody RC28-E for wet age-related macular degeneration and diabetic macular edema; and pipeline candidates such as the mesothelin-targeting ADC RC88, PD-L1 monoclonal antibody RC98, bispecific antibody RC148 and others including RC108 and RC278 in early clinical stages. Founded in 2008 and headquartered in Yantai, Shandong Province, China, the company maintains R&D centers and offices in Beijing, Shanghai, San Francisco and Washington, D.C., with GMP-compliant manufacturing capacity exceeding 70,000 liters supporting global clinical and commercial supply. RemeGen operates through integrated platforms for antibodies/fusion proteins, ADCs and multispecific antibodies, targeting unmet needs in China and international markets. In 2025, RemeGen licensed telitacicept ex-Greater China to Vor Biopharma for up to $4.23 billion including a $45 million upfront and $80 million warrants; entered an exclusive license with Santen for RC28-E in Greater China and Asia; reported positive Phase III data for telitacicept in Sjögren's syndrome and myasthenia gravis; secured FDA clearance for RC148 Phase II trials; and presented disitamab vedotin breakthroughs at ESMO and ASCO for urothelial and gastric cancers.
AbbVie, RemeGen partner on experimental solid tumor treatment
Short Interest in RemeGen Co., Ltd. (OTCMKTS:REGMF) Drops By 45.0%
RemeGen (OTCMKTS:REGMF) Trading Down 7.7% – Should You Sell?
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis
RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China
Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis